Abstract
Unknown degradation products of mycophenolate mofetil formed under oxidative stress conditions have been characterized via LC-MSn, using an RP-LC column (50 mm length, 2.1 mm i.d., 1.9 µm). The mobile phase consisted of 26 % acetonitrile and 74 % 9 mM ammonium acetate pH 5.87, the column temperature was set at 40 °C, and the flow rate of the mobile phase was 400 µL min−1. Four degradation products formed under the influence of 15 % hydrogen peroxide after an hour. Two of the degradation products had previously been identified as mycophenolic acid (m/z 321) and the N-oxide of mycophenolate mofetil (m/z 450). The other two unknown degradation products, denoted DP I (m/z 319) and DP II (m/z 466), were investigated in depth in order to identify their structures. The fragmentation patterns of DP I and DP II were established, analyzed, and compared to the fragmentation patterns of mycophenolate mofetil and the N-oxide of mycophenolate mofetil, which aided the elucidation of the structures of the unknown degradation products. The unknown degradation product DP I (m/z 319.2) was proposed to be an oxidized unsaturated mycophenolate aldehyde which also appeared as an ammonium adduct ion at m/z 336.3. The second unknown degradation product, DP II (m/z 466.3), was characterized as a doubly oxidized derivative of mycophenolate mofetil. A possible degradation pathway of mycophenolate mofetil under the influence of an oxidizing agent was also proposed.
References
Hesse CJ, Vantrimpont P, Van Riemsdijk-Van Overbeeke IC, Van Gelder T, Balk AHMM, Weimares W (2001) The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. Transplant Proc 33:2163–2164
Katzung BG (2004) Basic and clinical pharmacology, 9th edn. Lange, New York
Yin J, Wang S, Yang G, Yang G, Chen Y (2006) Molecularly imprinted solid-phase extraction for rapid screening of mycophenolic acid in human plasma. J Chromatogr B 844:142–147
Council of Europe (2014) European pharmacopoeia, 8th edn. Strasbourg, France
United States Pharmacopoeial Convention (2015) United States Pharmacopoeia 38—National Formulary 33. United States Pharmacopoeial Convention, Rockville
Pӑtruţescu C, Vlase G, Turcuş V, Ardelean D, Vlase T, Albu P (2015) TG/DTG/DTA data used for determining the kinetic parameters of the thermal degradation process of an immunosuppressive agent: mycophenolate mofetil. J Therm Anal Calorim 121:983–988
Tummala VBR, Nallagari SR, Golkonda R, Sure VV, Chintala R (2013) Development of stability indicating liquid chromatography–mass tandem spectrometric method for the estimation of mycophenolate mofetil in bulk and pharmaceutical formulations. J Pharm Res 7:640–646
Wang PY, Tong YF, Zhang JL, Wu CS, Wu S (2011) Determination of related impurities in the mycophenolate mofetil bulk drug by LC-ESI-FTICRMS/MSn. Chin J New Drugs 20(1):54–59
Golubović J, Protić A, Zečević M, Otašević B, Mikić M (2014) Artificial neural networks modelling in UPLC method optimization of mycophenolate mofetil and its degradation products. J Chemom 28:567–574
Choudhari VP, Nikalje APG (2014) Development and validation of stability indicating LC-PDA method for mycophenolate mofetil in presence of mycophenolic acid and its application for degradation kinetics and pH profile study. Adv Chem 719385. doi:10.1155/2014/719385
Brandl M, Comstock K, Cunniff J (2016) Degradation products profiling of mycophenolate mofetil using UHPLC and high resolution benchtop mass spectrometer. http://www.thermo.com.cn/Resources/201403/20141744953.pdf. Accessed 17 Mar 2016
Protić A, Lj Živanović, Radišić M, Laušević M (2011) Impurity profiling of mycophenolate mofetil with the assistance of desirability function in method development. J Liquid Chromatogr Relat Technol 34:1014–1035
ICH (2008) Topic Q3A (R2): impurities in new drug substances. Fed Regist 68:6924–6925
ICH (1998) Topic Q1CL: stability testing: requirements for new dosage forms. Fed Regist 62:25634–25635
ICH (2003) Topic Q1A (R2): stability testing of new drug substances and products. Fed Regist 68:65717–65718
ICH (1997) Topic Q1B: stability testing: photostability testing of new drug substances and products. Fed Regist 62:27115–27122
McLafferty FW, Tureček F (1993) Interpretation of mass spectra, 4th edn. University Science Books, Sausalito
Kuuranne T, Vahermo M (2000) Electrospray and atmospheric pressure chemical ionization tandem mass spectrometric behavior of eight anabolic steroid glucouronides. J Am Soc Mass Spectrom 11(8):722–730
Acknowledgments
These results are part of project no. 172033 financed by the Ministry of Education, Science and Technological Development of the Republic of Serbia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Protić, A., Radišić, M., Golubović, J. et al. Structural Elucidation of Unknown Oxidative Degradation Products of Mycophenolate Mofetil Using LC-MSn . Chromatographia 79, 919–926 (2016). https://doi.org/10.1007/s10337-016-3092-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-016-3092-2